Quantcast

Boehringer Ingelheim nets breakthrough therapy designation for Ofev, for chronic fibrosing interstitial lung diseases

FDA has granted to Boehringer Ingelheim a breakthrough therapy designation for Ofev, for Chronic Fibrosing ILDs with a Progressive Phenotype, after the study results from the Phase III testing met its primary endpoint and was recently published in the New England Journal of Medicine.

Read more